<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932724</url>
  </required_header>
  <id_info>
    <org_study_id>CY503C2</org_study_id>
    <secondary_id>EudraCT no. 2008-005536-32</secondary_id>
    <nct_id>NCT00932724</nct_id>
  </id_info>
  <brief_title>CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer</brief_title>
  <acronym>CY503C2</acronym>
  <official_title>Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytavis Biopharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cytavis Biopharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed as a phase II evaluation of the effect of CY-503 or placebo on
      progression free survival (PFS) defined as the time from start of treatment until the
      objective observation of progressive disease (PD) or death from any course in patients with
      chemotherapy-refractory metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer has a worldwide annual incidence of approximately 1 million new cases
      diagnosed yearly and it is the second leading cause of cancer-related death in Western
      nations. There are a couple of approved standard therapies for the treatment of MCRC with
      cytotoxic agents irinotecan, oxaliplatin, and the fluoropyrimidines , as well as bevacizumab,
      the antibody against vascular endothelial growth factor A, and cetuximab, the antibody
      against the epidermal growth factor receptor. But there are only a few studies achieving a
      median survival time of more than 20 months in MCRC patients with standard regimens. After a
      1st line therapy a high proportion (50% to 80%) of patients receives a 2nd line therapy with
      drugs not used in 1st line therapy and a part of them gets a 3rd line treatment. Results from
      a 2nd line therapy are best response rates ranging from 4 % - 23 %, a median PFS rate of 5.1
      months, a median TTP of 4.1 - 4.6 months and median overall survival 6.9 - 12 months.
      However, for patients who experience disease progression after standard therapy (definition
      see inclusion criteria) there is no further standard therapeutic option. These patients
      developed a resistance to these therapies and finally die of their disease. They generally
      get best supportive care (BSC). Thus, there is a need for new active treatment options in
      this setting.

      In this phase II double-blind placebo-controlled trial the efficacy and safety of CY-503, 350
      ng s.c. injected in patients with chemotherapy refractory MCRC are tested. Approved
      treatments given to MCRC patients are usually discontinued after a treatment over some weeks
      at the first detection of objective PD. It will be tested if CY-503 is able to achieve
      progression-free-survival (PFS) in comparison to placebo. Patients will initially be included
      to receive either CY-503 or placebo until documentation of objective PD.

      Standard therapy must be finished and has shown objective PD. Also patients with
      contraindications to standard therapy can be included.

      CY-503 shows the potential to improve treatment of MCRC. This study aims at evaluating the
      activity and therapeutic effects of the substance. Anticipated capabilities are substitution
      of cytostatic drugs or improvement of their efficacy and tolerability . Furthermore, the
      expected improvement of PFS rates after failure of standard chemotherapies has to be
      investigated.

      In a phase I trial CY-503 showed SD in patients who had exhausted standard therapy options
      for metastatic disease with subsequent disease progression with a median TTP of 17.4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The sponsor declared the early termination of the study due to poor recruitment of patients.
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor assessment by using CT scans and/or MRIs</measure>
    <time_frame>every 8 weeks (each 2 cycles)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>every 4 weeks (every cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life using a standardized questionaire</measure>
    <time_frame>every 4 weeks (every cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of survival by &quot;physical exam&quot;</measure>
    <time_frame>every 4 weeks (every cycle) / every 3 months during follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CY-503</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY-503</intervention_name>
    <description>Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks</description>
    <arm_group_label>CY-503</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age ≥ 18 years

          -  Patients are eligible with diagnosis of measurable metastatic colorectal carcinoma and
             radiologic documentation of disease progression during or with 3 months after
             termination of standard chemotherapy (fluoropyrimidine-based therapy with oxaliplatin
             and irinotecan). Patients who had to interrupt the 1st or 1nd line therapy due to
             intolerance or who were refractory or intolerant to the standard treatment regimens
             are eligible, too. Bevacizumab can, but does not need to be administered at discretion
             of treating physician. Patients with K-RAS wild-type can be treated with cetuximab or
             panitumumab before they enter the study.

          -  No chemotherapy within 4 weeks before treatment start

          -  No residual significant toxicity (greater than NCI grade 1), in case of peripheral
             neuropathy: no symptoms of peripheral neuropathy of NCI CTC grade 4 within 4 weeks
             before treatment start.

          -  No previous treatment with experimental therapies after standard therapies is allowed.

          -  Patients must use effective contraception if of reproductive potential. Females must
             not be pregnant or lactating

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 2

          -  WBC ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count
             ≥100,000/mm3

          -  Bilirubin ≤ 2.0 mg/dL (40 μmol/L) (unless due to Gilbert's syndrome in which case the
             bilirubin should be ≤3.5 mg/dL (59.86 μmol/L)), aspartate transaminase (AST)/alanine
             transaminase (ALT) ≤ 5 × upper limit of normal (ULN); hepatic alkaline phosphatase ≤
             3.0 × ULN (in case of liver metastases higher levels do not hinder inclusion of
             patients)

          -  Serum creatinine ≤ 2.0 mg/dL (180 μmol/L)or creatinine clearance &gt;= 50 ml/min. ,
             proteinuria &lt; 2.0 g/24 hr urine collection in patients with a positive urine dipstick
             for protein

          -  Written informed consent according to ICH-GCP and national laws and regulations prior
             to receipt of any trial medication or beginning trial procedures

        Exclusion Criteria:

          -  Evidence of any other malignant disease (with the exception of tumors operatively
             cured at least 5 years prior to the trial)

          -  Known brain metastases

          -  Uncontrolled pleural effusions

          -  Interstitial pneumonitis or pulmonary fibrosis

          -  Severe/ unstable systemic disease or infection and circumstances not permitting trial
             participation (e.g., alcoholism or substance abuse)

          -  Unstable cardiac disease in the last 6 months

          -  Use of conventional mistletoe preparations, any immunostimulating substances and/or
             monoclonal antibodies within four weeks prior to and during the trial - ongoing
             therapy with steroids is permitted if the dose is not higher than 20 mg of
             prednisone-equivalent at the time of inclusion and during this clinical trial

          -  Any evidence or history (elicited by the investigator) of symptomatic cerebrovascular
             events (i.e., stroke or transient ischemic attack) within 6 months prior to
             randomization

          -  Any history or evidence of pulmonary embolism or thrombophlebitis (including deep vein
             thrombosis) requiring anticoagulant therapy (e.g., marcumar or heparin)

          -  History of hypersensitivity to mistletoe

          -  History of primary immunodeficiency

          -  Known human immunodeficiency virus (HIV) or known active viral hepatic infections

          -  Prior treatment with CY-503

          -  A general medical or psychological condition or behaviour, including substance
             dependence or abuse that, in the opinion of the investigator, might not permit the
             patient to complete the trial or sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Zwierzina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Innsbruck, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lothar Bergmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Hall</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vinzenz Krankenhaus Zams</name>
      <address>
        <city>Zams</city>
        <zip>6511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land GmbH</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien GmbH am Klinikum St. Marien</name>
      <address>
        <city>Amberg</city>
        <zip>922224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum f. Hämatologie, Onkologie u. Diabetologie</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund GmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Tumorzentrum - Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>7370</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang-Universität Frankfurt</name>
      <address>
        <city>Frankfurt a.M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther Universität Halle</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Heidelberg - Nationales Centrum f. Tumorerkrankungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hildesheim</city>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hof</city>
        <zip>95028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Onkologie</name>
      <address>
        <city>Köln</city>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanness-Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und internistische Onkologie</name>
      <address>
        <city>München</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis f. Hämatologie u. Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis, Hämatologie und Onkologie</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nordoberpfalz AG</name>
      <address>
        <city>Weiden Oberpfalz</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <name_title>Prof. Hans Lentzen, PhD</name_title>
    <organization>Cytavis Biopharma GmbH</organization>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Cancer</keyword>
  <keyword>refractory</keyword>
  <keyword>Phase II</keyword>
  <keyword>randomised</keyword>
  <keyword>double-blind</keyword>
  <keyword>controlled</keyword>
  <keyword>multicenter</keyword>
  <keyword>CY-503</keyword>
  <keyword>Cytavis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

